Literature DB >> 2126278

Varying dose-response characteristics of different immunoassays and an in-vitro bioassay for FSH are responsible for changing ratios of biologically active to immunologically active FSH.

F Jockenhövel1, S A Khan, E Nieschlag.   

Abstract

Serum FSH levels in fertile and infertile men were determined by applying the Sertoli cell in-vitro bioassay and six different immunoassays. Bioassay and immunoassay estimates were significantly correlated (r ranging from 0.78 to 0.86; P less than 0.01). On average, all immunoassays measured lower FSH concentrations in samples with low FSH levels and higher FSH concentrations in those with high FSH levels compared with the bioassay. Ratios of bioactivity to immunoreactivity (B/I) were highest in fertile men and lowest in men with severe disturbances of testicular function. Depending on which immunoassay was used these differences were either significant or only marginal. Dose-response characteristics for WHO FSH standard preparation 78/549, used in the bioassay as well as in the immunoassays, were different between immunoassays and the bioassay, suggesting that decreasing B/I ratios with increasing FSH serum levels were method-related and reflected different slopes of the dose-response characteristics of the assays, rather than being true changes in the molecular composition of FSH. The present investigation underlines the necessity of choosing the immunoassay used for comparison with the bioassay carefully and of validating the system in regard to parallelism between dose-response characteristics. B/I ratios must be interpreted with great caution and previous studies which report changing B/I ratios in various endocrine situations may have to be reevaluated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126278     DOI: 10.1677/joe.0.1270523

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  3 in total

Review 1.  In vitro bioassays of follicle-stimulating hormone: methods and clinical applications.

Authors:  M Simoni; E Nieschlag
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

2.  Molecular composition of two different batches of urofollitropin: analysis by immunofluorimetric assay, radioligand receptor assay and in vitro bioassay.

Authors:  M Simoni; G F Weinbauer; E Nieschlag
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

3.  Sulfhydryl oxidase immunoreactivity in seminiferous tubules of infertile men.

Authors:  M Bergmann; G Aumüller; J Seitz; E Nieschlag
Journal:  Cell Tissue Res       Date:  1992-02       Impact factor: 5.249

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.